182 related articles for article (PubMed ID: 27229914)
1. Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics.
Villarreal AE; O'Bryant SE; Edwards M; Grajales S; Britton GB;
Neurodegener Dis Manag; 2016 Jun; 6(3):203-13. PubMed ID: 27229914
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
[TBL] [Abstract][Full Text] [Related]
3. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
4. Serum thyroid-stimulating hormone as a predictor of cognitive impairment in an elderly cohort.
Forti P; Olivelli V; Rietti E; Maltoni B; Pirazzoli G; Gatti R; Gioia MG; Ravaglia G
Gerontology; 2012; 58(1):41-9. PubMed ID: 21430364
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
[TBL] [Abstract][Full Text] [Related]
6. Identification of peripheral inflammatory markers between normal control and Alzheimer's disease.
Kim SM; Song J; Kim S; Han C; Park MH; Koh Y; Jo SA; Kim YY
BMC Neurol; 2011 May; 11():51. PubMed ID: 21569380
[TBL] [Abstract][Full Text] [Related]
7. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
8. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease.
Diniz BS; Teixeira AL; Ojopi EB; Talib LL; Mendonça VA; Gattaz WF; Forlenza OV
J Alzheimers Dis; 2010; 22(4):1305-11. PubMed ID: 20930310
[TBL] [Abstract][Full Text] [Related]
9. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease.
Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW
Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077
[TBL] [Abstract][Full Text] [Related]
10. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.
Muenchhoff J; Poljak A; Song F; Raftery M; Brodaty H; Duncan M; McEvoy M; Attia J; Schofield PW; Sachdev PS
J Alzheimers Dis; 2015; 43(4):1355-73. PubMed ID: 25159666
[TBL] [Abstract][Full Text] [Related]
11. Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology.
Kleinschmidt M; Schoenfeld R; Göttlich C; Bittner D; Metzner JE; Leplow B; Demuth HU
J Alzheimers Dis; 2016; 50(1):111-26. PubMed ID: 26639953
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine, vitamin B12, and folic acid levels in Alzheimer's disease, mild cognitive impairment, and healthy elderly: baseline characteristics in subjects of the Australian Imaging Biomarker Lifestyle study.
Faux NG; Ellis KA; Porter L; Fowler CJ; Laws SM; Martins RN; Pertile KK; Rembach A; Rowe CC; Rumble RL; Szoeke C; Taddei K; Taddei T; Trounson BO; Villemagne VL; Ward V; Ames D; Masters CL; Bush AI
J Alzheimers Dis; 2011; 27(4):909-22. PubMed ID: 21891867
[TBL] [Abstract][Full Text] [Related]
13. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment.
Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM
Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609
[TBL] [Abstract][Full Text] [Related]
14. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
[TBL] [Abstract][Full Text] [Related]
15. Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: a molecular neuropsychology approach.
Edwards M; Balldin VH; Hall J; O'Bryant S
J Alzheimers Dis; 2014; 42(2):635-40. PubMed ID: 24916542
[TBL] [Abstract][Full Text] [Related]
16. Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.
Jongbloed W; van Dijk KD; Mulder SD; van de Berg WD; Blankenstein MA; van der Flier W; Veerhuis R
J Alzheimers Dis; 2015; 46(4):1103-10. PubMed ID: 26402636
[TBL] [Abstract][Full Text] [Related]
17. Circulating levels of IL-1 family cytokines and receptors in Alzheimer's disease: new markers of disease progression?
Italiani P; Puxeddu I; Napoletano S; Scala E; Melillo D; Manocchio S; Angiolillo A; Migliorini P; Boraschi D; Vitale E; Di Costanzo A
J Neuroinflammation; 2018 Dec; 15(1):342. PubMed ID: 30541566
[TBL] [Abstract][Full Text] [Related]
18. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
[TBL] [Abstract][Full Text] [Related]
19. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
20. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
